Downregulation of ILK expression and CDDP treatment, in combination, is a more effective approach for the treatment of lung cancer through affecting downstream gene expression, including p-GSK3β, p-AKT, AP-1, β-catenin, cyclin D1 and MMP-9. The gene discussed is GSK3B; the disease is lung carcinoma.